Goldman Sachs Group Inc Anavex Life Sciences Corp. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 293,780 shares of AVXL stock, worth $2.65 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
293,780
Previous 411,659
28.64%
Holding current value
$2.65 Million
Previous $3.53 Million
23.33%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding AVXL
# of Institutions
196Shares Held
32MCall Options Held
1.16MPut Options Held
804K-
Black Rock Inc. New York, NY6.39MShares$57.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$46 Million0.0% of portfolio
-
State Street Corp Boston, MA2.95MShares$26.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$18.2 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA1.02MShares$9.23 Million0.83% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $702M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...